Literature DB >> 3990380

Elevated bone aluminum content in dialysis patients without osteomalacia.

J T McCarthy, S B Kurtz, J T McCall.   

Abstract

In almost all dialysis patients, bone aluminum content (BAC) is elevated in comparison with levels in normal subjects. Extremely high BAC (200 micrograms or more of aluminum per gram of bone) is significantly associated with classic aluminum-related osteomalacia. We noted three patients with elevated BAC but without histologic evidence of typical osteomalacia. Two of the patients had moderately severe osteitis fibrosa (hyperparathyroidism), and one patient had mixed uremic bone disease--predominantly hyperparathyroidism but some impairment of bone mineralization as well. As has recently been reported by others, the deferoxamine infusion test yielded unusual results in these patients. On the basis of our observations, we believe that an isolated measurement of BAC to determine whether aluminum-related osteomalacia is present has certain limitations. Aluminum-related bone disease can be accurately diagnosed only with use of bone histomorphometry. Elevated levels of immunoreactive parathyroid hormone may offer protection from the toxic effects of aluminum.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3990380     DOI: 10.1016/s0025-6196(12)60539-4

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  1 in total

1.  Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy.

Authors:  M Yaqoob; R Ahmad; P McClelland; K A Shivakumar; D F Sallomi; I H Fahal; N B Roberts; T Helliwell
Journal:  Postgrad Med J       Date:  1993-02       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.